AP NEWS

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 16, 111, 91, 4, 80, 14 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 13, 8 and 16 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Kidney Cancer (Renal Cell Cancer) - Overview Kidney Cancer (Renal Cell Cancer) - Therapeutics Development Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development Kidney Cancer (Renal Cell Cancer) - Drug Profiles Kidney Cancer (Renal Cell Cancer) - Dormant Projects Kidney Cancer (Renal Cell Cancer) - Discontinued Products Kidney Cancer (Renal Cell Cancer) - Product Development Milestones Appendix For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/s8pgfl/kidney_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006166/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Kidney Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 04:13 PM/DISC: 09/25/2018 04:13 PM

http://www.businesswire.com/news/home/20180925006166/en

AP RADIO
Update hourly